Filing Details

Accession Number:
0000899243-18-007987
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-19 17:27:27
Reporting Period:
2018-03-19
Accepted Time:
2018-03-19 17:27:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1724521 Arcus Biosciences Inc. RCUS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1422996 C. Juan Jaen C/O Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward CA 94545
President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-03-19 2,175,150 $0.00 2,667,574 No 4 C Indirect By Trust
Common Stock Acquisiton 2018-03-19 66,666 $15.00 2,734,240 No 4 P Indirect By Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By Trust
No 4 P Indirect By Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2018-03-19 2,020,202 $0.00 2,020,202 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-03-19 125,012 $0.00 125,012 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2018-03-19 29,936 $0.00 29,936 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 189,393 Direct
Footnotes
  1. The total represents shares received upon conversion of shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock.
  2. The reported security converted into the Issuer's Common Stock on a 1-for-1 basis automatically immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date.
  3. Represents shares purchased in the Issuer's initial public offering.
  4. The total includes 126,262 shares of Common Stock acquired by the Reporting Person on January 17, 2018 for $5.39 per share pursuant to the exercise of an option granted on January 4, 2018.
  5. Represents shares of Series C Convertible Preferred Stock indirectly owned by the Reporting Person as a result of a trust's purchase of such shares from the Issuer on November 6, 2017 for $11.6915 per share.